Advertisement
News
Advertisement

Max Neeman International Completes Targeted Enrollment of 15,000 for Large Ph IV Study

Tue, 04/12/2011 - 8:37am
Bio-Medicine.Org

RESEARCH TRIANGLE PARK, N.C., April 12, 2011 /PRNewswire/ -- Max Neeman meets enrollment and timeline of 15,000 for a large, Phase IV metabolic disorder trial across 1200 sites throughout India. As a leading Indian CRO, the company has completed multiple Phase IV studies for global sponsors with thousands of patients successfully enrolled.  A 30,000 patient enrollment study across 1500 sites is currently in-process with four more in the pipeline.

(Logo: http://photos.prnewswire.com/prnh/20110105/CL25129LOGO)

Current Ph IV success and activities are due to a specific business model Max Neeman created for such 'Observational studies' based on over 10 years of experience. Segments of the business model include: zonal stratification of >1000 sites and SOPs to improve quality of patient data retrieved in large studies. More than 30 CSRs have been developed to date.

The prevalence of diabetes in India is only second to China with 50.8 million people diagnosed with the disease and expected to rise steeply in the coming years. More large Ph IV studies are predicted and Max Neeman is prepared with a Ph IV strategy that is a combination of operational excellence (via Six Sigma practices), dedicated and trained project management teams, flexible delivery models, a customized approach and integrated technology. All these combine to deliver positive results on a customer's objective in a swift and cost effective manner.

About Max Neeman International

Max Neeman International is one of the leading and largest CROs in India and the clinical research arm of healthcare conglomerate, Max India.  Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP

'/>"/>

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading